Z 350

an alpha(1)-adrenoceptor antagonist; structure in first source

Also Known As:

4-(3-(4-(1-(4-methylphenyl)-3-(4-(2-methoxyphenyl)piperazine-1-yl)propoxy)benzoyl)indole-1-yl)butyric acid; Z-350

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 06/01/1999 - "It is expected that Z-350 will be a candidate drug for the treatment of benign prostatic hyperplasia." 09/01/1999 - "These results indicate that Z-350 exhibited alpha(1)-adrenoceptor-antagonistic and 5alpha-reductase inhibitory actions at almost equal doses in vivo, and was expected to improve the bladder outlet obstruction associated with benign prostatic hyperplasia with smaller cardiovascular adverse effect."
2.	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 09/01/1999 - "These results indicate that Z-350 exhibited alpha(1)-adrenoceptor-antagonistic and 5alpha-reductase inhibitory actions at almost equal doses in vivo, and was expected to improve the bladder outlet obstruction associated with benign prostatic hyperplasia with smaller cardiovascular adverse effect."